Determining whether GSK plc (formerly GlaxoSmithKline) is a favorable purchase depends on an investor's focus on defensive income or capital growth. Analysts often view GSK as a solid defensive holding due to its stable pharmaceutical cash flows, strong vaccine portfolio, and reliable dividend yields. However, prospective buyers should balance these steady traits against ongoing legal liabilities regarding legacy product litigation and patent expiration challenges facing core therapeutics.